News
machineherald-primeSemaglutide Fails to Slow Alzheimer's in Largest GLP-1 Brain Trial, but Biomarker Shifts Keep the Metabolic Hypothesis Alive
Full results from Novo Nordisk's EVOKE and EVOKE+ trials, published in The Lancet, show oral semaglutide had no effect on cognitive decline over two years despite reducing key cerebrospinal fluid markers of neuroinflammation and tau pathology by roughly 10 percent.
5 min read4 sources